Krystal Biotech Stock Profit Margin
| KRYS Stock | USD 157.68 4.08 2.52% |
Krystal Biotech fundamentals help investors to digest information that contributes to Krystal Biotech's financial success or failures. It also enables traders to predict the movement of Krystal Stock. The fundamental analysis module provides a way to measure Krystal Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Krystal Biotech stock.
| Last Reported | Projected for Next Year | ||
| Net Profit Margin | 0.19 | 0.20 |
Krystal | Profit Margin |
Krystal Biotech Company Profit Margin Analysis
Krystal Biotech's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Krystal Biotech Profit Margin | 0.60 % |
Most of Krystal Biotech's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Krystal Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Krystal Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Krystal Biotech is extremely important. It helps to project a fair market value of Krystal Stock properly, considering its historical fundamentals such as Profit Margin. Since Krystal Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Krystal Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Krystal Biotech's interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Krystal Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Krystal Biotech has a Profit Margin of 0.5957%. This is 105.31% lower than that of the Biotechnology sector and 102.59% lower than that of the Health Care industry. The profit margin for all United States stocks is 146.91% lower than that of the firm.
Krystal Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Krystal Biotech's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Krystal Biotech could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics of similar companies.Krystal Biotech is currently under evaluation in profit margin category among related companies.
Krystal Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Krystal Biotech from analyzing Krystal Biotech's financial statements. These drivers represent accounts that assess Krystal Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Krystal Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 232.8M | 880.6M | 1.6B | 2.0B | 3.4B | 3.5B | |
| Enterprise Value | 129.1M | 696.3M | 1.2B | 1.9B | 3.0B | 3.2B |
Krystal Fundamentals
| Return On Equity | 0.0887 | ||||
| Return On Asset | -0.0497 | ||||
| Profit Margin | 0.60 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 4.09 B | ||||
| Shares Outstanding | 28.56 M | ||||
| Shares Owned By Insiders | 12.75 % | ||||
| Shares Owned By Institutions | 91.45 % | ||||
| Number Of Shares Shorted | 2.45 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 5.78 X | ||||
| Price To Sales | 46.93 X | ||||
| Revenue | 50.7 M | ||||
| EBITDA | (92.22 M) | ||||
| Net Income | 10.93 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 8.09 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.45 X | ||||
| Book Value Per Share | 28.02 X | ||||
| Cash Flow From Operations | (88.8 M) | ||||
| Short Ratio | 7.84 X | ||||
| Earnings Per Share | 2.18 X | ||||
| Target Price | 189.0 | ||||
| Number Of Employees | 229 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 4.5 B | ||||
| Total Asset | 818.36 M | ||||
| Retained Earnings | (269.83 M) | ||||
| Working Capital | 554.82 M | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
| Net Asset | 818.36 M |
About Krystal Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Krystal Biotech Piotroski F Score and Krystal Biotech Altman Z Score analysis. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Krystal Stock analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.18 | Revenue Per Share 3.451 | Return On Assets (0.05) | Return On Equity 0.0887 |
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.